Menu

Pharma News

2018 V19A18

Top 10 most read GaBI Online articles in 2018

Home/Pharma News | Posted 18/01/2019

A review of the important events for biosimilars during 2018 are presented in this article. Some of the most memorable events for biosimilars in 2018 were the rejections by the US Food and Drug Administration (FDA) of four biosimilars and the agency’s update on its naming guideline for biologicals. Other subjects of interest for biosimilars were European Medicines Agency approvals, the US biosimilars market, biosimilar policies in Europe, position statements on biosimilars and interchangeability and switching.

11 AA010165

Samsung BioLogics sues Korea’s FSC over accounting discrepancies

Home/Pharma News | Posted 11/01/2019

Samsung BioLogics is fighting back against allegations of accounting fraud and has launched a lawsuit against the South Korean financial authority, the Financial Services Commission (FSC).

Discount Save money V15c13

Health care in Iraq saves money by incorporating off-patent biologicals

Home/Pharma News | Posted 14/12/2018

Iraq is one of many countries determined to increase its budget savings by replacing appropriate originator biologicals with off-patent biologicals. This is due to the recognition of the proven impact off-patent biologicals have on the financial burden of healthcare systems worldwide [1, 2].

Shaking hands V13D29

Alvotech makes deal with Fuji Pharma for biosimilars in Japan

Home/Pharma News | Posted 30/11/2018

Iceland-based biopharmaceutical company Alvotech and Japan-based Fuji Pharma announced on 19 November 2018 that they had entered into an exclusive partnership for biosimilars in Japan.

20893354_l

Amgen collaborates with Orion to market Amgevita in Finland

Home/Pharma News | Posted 16/11/2018

The Orion Group announced on 24 October 2018 that it will distribute Amgen’s adalimumab biosimilar in Finland.

45 AA005795

Biosimilar partnerships for Alvotech and Pall Biotech

Home/Pharma News | Posted 19/10/2018

Partnering to develop biosimilars is still in vogue. The latest companies to join the trend include Alvotech with Changchun High & New Technology Industries Group (CCHN) and Pall Corporation’s Biotech business (Pall Biotech) with Aetos Biologics.

Teamwork check mark V13D12

Mundipharma buys Spanish biosimilars maker Cinfa Biotech

Home/Pharma News | Posted 12/10/2018

UK-based Mundipharma International (Mundipharma) is strengthening its position in biosimilars with the acquisition of Spanish biosimilars maker Cinfa Biotech.

Chemo Farmalan1 V17F08

MENA mAb manufacturer AryoGen receives EU GMP approval

Home/Pharma News | Posted 28/09/2018

Iran-based AryoGen Pharmed (AryoGen) has received a Good Manufacturing Practice (GMP) certificate from the European Medicines Agency (EMA), becoming one of the first monoclonal antibody (mAb) manufacturers in the Middle East and North Africa (MENA) region to be certified [1].

Shaking hands V13D29

Co-development deal for ranibizumab biosimilar Xlucane

Home/Pharma News | Posted 07/09/2018

German generics giant Stada and Swedish biotech company Xbrane announced on 12 July 2018 that they had entered into a co-development agreement for Xlucane, a proposed biosimilar to Lucentis (ranibizumab).

Teamwork questionmark V13D05

AbbVie signs another licensing deal for adalimumab biosimilar

Home/Pharma News | Posted 31/08/2018

US-based pharma giant AbbVie has signed yet another licensing deal for a biosimilar version of its blockbuster arthritis drug Humira (adalimumab).